MedPath

THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation

Phase 3
Completed
Conditions
Hyponatremia
Interventions
Drug: Placebo
Registration Number
NCT00578695
Lead Sponsor
CardioKine Inc.
Brief Summary

The purpose of this study is to determine the safety and efficacy of lixivaptan in the treatment of hyponatremia in patients with congestive heart failure.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
652
Inclusion Criteria
  • Male and female patients 18 years of age or older with hyponatremia and hospitalized for congestive heart failure.
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboPlacebo
ActivelixivaptanLixivaptan
Primary Outcome Measures
NameTimeMethod
To determine whether lixivaptan can effectively and safely produce an increase in serum sodium from Baseline in heart failure subjects with hyponatremia and volume overload. Effects on body weight and other clinical measures will be evaluated.60 days
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (24)

Research Site 1

🇪🇸

Vigo, Spain

Research Site

🇨🇭

Geneva, Switzerland

University of Iowa Hospitals and Clinics

🇺🇸

Iowa City, Iowa, United States

Northern Michigan Hospital

🇺🇸

Petoskey, Michigan, United States

Siant Barnabas Medical Center

🇺🇸

Livingston, New Jersey, United States

Research Site 2

🇵🇱

Krakow, Poland

Research Site1

🇺🇸

Sayre, Pennsylvania, United States

hospital Interzonal General de Agudos, "Eva Peron" (HIGA)

🇦🇷

San Martin, Buenos Aires, Argentina

Hospital Militar Central H Gral. 601 "Cirujano Mayor Dr. Cosme Argerich"

🇦🇷

Buenos Aires, Argentina

Hospital de Clinicas "Jose de San Martin"

🇦🇷

Buenos Aires, Argentina

Scroll for more (14 remaining)
Research Site 1
🇪🇸Vigo, Spain

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.